<br>        Inclusion Criteria:<br><br>          -  Subjects must provide written informed consent prior to performance of study-specific<br>             procedures or assessments, and must be willing to comply with treatment and follow up.<br><br>          -  Age = 18 years.<br><br>          -  Histologically confirmed adenocarcinoma of the stomach or the gastroesophageal<br>             junction with either metastatic or locally advanced disease, incurable by operation.<br><br>          -  Eastern Cooperative Oncology Group (ECOG) performance status of < or = 2<br><br>          -  At least one unidimensional, measurable tumor parameter (according to RECIST 1.1)<br><br>          -  No preceding cytotoxic therapy (neoadjuvant or adjuvant treatment allowed if finished<br>             > 6 months before inclusion)<br><br>          -  Adequate organ system function.<br><br>          -  Men and women must perform an adequate contraception.<br><br>          -  Female subjects who are lactating should discontinue nursing prior to the first dose<br>             of study drug and should refrain from nursing throughout the treatment period and for<br>             14 days following the last dose of study drug.<br><br>        Exclusion Criteria:<br><br>          -  Prior malignancy, except for curatively treated basal cell carcinoma of the skin and<br>             in situ carcinoma of the cervix.<br><br>          -  Overexpression of HER-2, defined as IHC 3+ or IHC 2+ and FISH positive.<br><br>          -  Known hypersensitivity against 5-FU, leukovorin, oxaliplatin or other platinum<br>             compounds or pazopanib.<br><br>          -  History or clinical evidence of central nervous system (CNS) metastases or<br>             leptomeningeal carcinomatosis.<br><br>          -  Clinically significant gastrointestinal abnormalities that may increase the risk for<br>             gastrointestinal bleeding or the absorption of investigational product<br><br>          -  Presence of uncontrolled infection.<br><br>          -  Corrected QT interval (QTc) > 480 ms using Bazett's formula.<br><br>          -  History of any one or more of the following cardiovascular conditions within the past<br>             6 months: cardiac angioplasty or stenting, myocardial infarction, unstable angina,<br>             coronary artery bypass graft surgery, symptomatic peripheral vascular disease, NYHA<br>             III or IV congestive heart failure.<br><br>          -  Poorly controlled hypertension.<br><br>          -  History of cerebrovascular accident including transient ischemic attack (TIA),<br>             pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.<br><br>          -  Prior major surgery or trauma within 28 days prior to first dose of study drug and/or<br>             presence of any non-healing wound, fracture, or ulcer.<br><br>          -  Evidence of active bleeding or bleeding diathesis.<br><br>          -  Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels.<br><br>          -  Hemoptysis in excess of 2.5 ml within 8 weeks of first dose of study drug.<br><br>          -  Any serious and/or unstable pre-existing medical, psychiatric, or other condition that<br>             could interfere with subject's safety, provision of informed consent, or compliance to<br>             study procedures.<br><br>          -  Unable or unwilling to discontinue use of prohibited medications for at least 14 days<br>             or five half-lives of a drug (whichever is longer) prior to the first dose of study<br>             drug and for the duration of the study.<br><br>          -  Treatment with any of the following anti-cancer therapies: radiation therapy, surgery<br>             or tumor embolization within 14 days prior to the first dose of pazopanib OR<br>             chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal<br>             therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the<br>             first dose of pazopanib. A neoadjuvant or adjuvant chemotherapy must be finished at<br>             least 6 month before study entry.<br><br>          -  Any ongoing toxicity from prior anti-cancer therapy that is >Grade 1 and/or that is<br>             progressing in severity, except alopecia.<br><br>          -  Grade 3 or 4 diarrhea.<br><br>          -  Peripheral polyneuropathy > NCI Grade.<br><br>          -  Pregnant or lactating women.<br><br>          -  Men or women who are planning a pregnancy within the next six months.<br><br>          -  Participation in another clinical trial with investigational agents within the last 30<br>             days prior to study start.<br><br>          -  The patient is a colleague or employed by the study investigator or by an involved<br>             institution including the sponsor of the study.<br><br>          -  Patient is detained in a psychiatric unit or imprisoned.<br>